Command Palette

Search for a command to run...

Preprint WatchModerateAugust 26th, 2026

IL-12 restores the sequential cytotoxic capacities of anti-GD2 CAR-T and CAR-iNKT cells against glioblastoma

Tran, T.-D.; Lamorlette, C.; Gerard, L.; Brouard, J.; Dotti, G.; Moulin, D.; Reppel, L.; Pochon, C.; Rubio, M.-T.

IL-12 restores the sequential cytotoxic capacity of anti-GD2 CAR-T and CAR-iNKT cells against glioblastoma cells that have evaded a first round of killing, identifying IL-12 supplementation as a route around tumour-mediated CAR exhaustion.

Moderate contradiction

1 prior failure

Two documented clinical failures match this mechanism, or a single Phase 3 failure is on record.

IL-12 as a solid tumour immunotherapy has one efficacy failure on the Claidex record, which is what sets this flag at MODERATE. cln-617-il12b-il2-fusion-solid-tumors-phase1-efficacy-termination was an intratumoural IL-12 and IL-2 fusion protein in advanced solid tumours that stopped in Phase 1 for insufficient effect, and it tested IL-12 as a standalone microenvironment agent rather than as a support cytokine for adoptive cells. The preprint uses IL-12 in the second role, where the readout is CAR persistence rather than tumour regression, so the prior failure does not contradict it. It does argue for measuring the CAR-cell effect and the direct antitumour effect separately, because the earlier program showed that IL-12 delivered to a tumour does not by itself produce responses.

Abstract excerpt

Glioblastoma (GBM) is a highly aggressive brain tumor characterized by rapid progression and a poor prognosis. CAR-based cellular therapies are promising approaches, and CAR-T cells targeting GD2 have demonstrated transient efficacy. Identifying how tumors evade these treatments is essential for advancing therapy development. In this study, we investigated the mechanisms through which GBM cells evade GD2.chimeric antigen receptor (CAR)-T and CAR-invariant natural killer T (iNKT) in vitro and explored ways to overcome tumor escape. GD2-targeted CAR-T and CAR-iNKT cells were tested in a stepwise in vitro model that repeatedly exposed them to GD2+ cell lines. While CAR effector cells effectively killed GD2+ GBM cells in short-term assays, their anti-tumor efficacy declined after repeated antigen exposures. Tumor escape mechanisms included reduced CAR expression, impaired proliferation, reduced production of cytokine, granzyme, and perforin, tumor downregulation of GD2, trogocytosis, and upregulation of the HLA-E/NKG2A inhibitory compared to MICA-B/NKG2D activation pathways on tumor and immune cells. Increasing effector cell numbers or adding IL-15 +/- IL-7 partially improved CAR persistence but did not fully restore CAR effector functions. By contrast, IL-12 addition optimized tumor-killing capacity by increasing CAR effector cell proliferation, CAR surface expression, IFN-y production, and balancing HLA-E/NKG2A versus MICA-B/NKG2D pathways. In conclusion, GD2.CAR-T and GD2.CAR-iNKT cells effectively target GBM but are susceptible to repeated antigen exposure, which IL-12 could counteract. These findings encourage further development of armored IL-12 CAR-T or CAR-iNKT cells and further investigation of the roles of HLA-E and MICA-B pathways in immunotherapy against GBM.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.